NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis $0.01 +0.00 (+11.11%) As of 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About ProPhase Labs Stock (NASDAQ:PRPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProPhase Labs alerts:Sign Up Key Stats Today's Range$0.0085▼$0.0150-Day Range$0.01▼$0.0552-Week Range$0.01▼$5.44Volume1.39 million shsAverage Volume238,339 shsMarket Capitalization$209.12 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ProPhase Labs, Inc. is a diversified health and wellness company that develops and commercializes consumer health products, diagnostic services and genomic information solutions. The company’s activities have included over-the-counter products, laboratory testing and technologies designed to support personalized health and wellness. ProPhase Labs is known for Cold-EEZE zinc products, including lozenges and other cold-related remedies. Through its diagnostic operations, the company has provided molecular testing and related laboratory services, including testing developed for infectious diseases. Its business has also included genomic services and data-focused offerings intended to help consumers better understand their genetic information. The company was formerly known as The Quigley Corporation and adopted the ProPhase Labs name as it expanded beyond its traditional consumer healthcare business. ProPhase Labs is headquartered in Garden City, New York, and primarily serves the U.S. market through its consumer products, laboratory operations and health technology initiatives. Ted Karkus has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRPH Stock News HeadlinesProPhase Labs (NASDAQ:PRPH) Stock Breaks Below 200 Day Moving Average - Here's What HappenedOctober 8, 2026 | americanbankingnews.comAurora Cannabis (NASDAQ:ACB) & ProPhase Labs (NASDAQ:PRPH) Financial ComparisonOctober 7, 2026 | americanbankingnews.comDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 14 at 1:00 AM | Profits Run (Ad)ProPhase Labs Delays Quarterly SEC FilingAugust 14, 2026 | tipranks.comProPhase Labs Inc.July 16, 2026 | marketwatch.comProPhase Labs Announces Immediate Resignation of Board MemberJune 25, 2026 | theglobeandmail.comProPhase Labs Delays Quarterly Financial FilingMay 15, 2026 | tipranks.comProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections PlatformApril 15, 2026 | globenewswire.comSee More Headlines PRPH Stock Analysis - Frequently Asked Questions How have PRPH shares performed this year? ProPhase Labs' stock was trading at $0.4475 on January 1st, 2026. Since then, PRPH shares have decreased by 97.8% and is now trading at $0.01. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings data on Wednesday, November, 19th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.50. The firm earned $0.88 million during the quarter, compared to analysts' expectations of $5.69 million. ProPhase Labs had a negative trailing twelve-month return on equity of 482.05% and a negative net margin of 825.01%. Read the conference call transcript. When did ProPhase Labs' stock split? ProPhase Labs shares reverse split before market open on Monday, December 22nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Ford Motor (F), NIO (NIO), Bollinger Innovations (BINI), Lucid Group (LCID) and Alliance Resource Partners (ARLP). Company Calendar Last Earnings11/19/2025Today10/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PRPH's financial health is in the Red zone, according to TradeSmith. PRPH has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRPH CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees130Year Founded1981Profitability EPS (Trailing Twelve Months)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.36 million Net Margins-825.01% Pretax Margin-680.20% Return on Equity-482.05% Return on Assets-88.90% Debt Debt-to-Equity Ratio0.14 Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$5.06 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.00Miscellaneous Outstanding Shares20,912,000Free Float5,444,000Market Cap$209.12 thousand OptionableNo Data Beta0.13 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:PRPH) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
